Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Avadel Pharmaceuticals PLC | AVDL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.82 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 9.50 - 18.85 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 17.82 | USD |
Avadel Pharmaceuticals (AVDL) Options Flow Summary
Avadel Pharmaceuticals PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
0 | 0.00 | - | 27.96M | -160.28M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Avadel Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVDL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 17.25 | 18.45 | 16.70 | 17.62 | 870,789 | 0.57 | 3.30% |
1 Month | 17.00 | 18.85 | 15.25 | 17.17 | 954,355 | 0.82 | 4.82% |
3 Months | 14.48 | 18.85 | 11.82 | 15.54 | 1,226,158 | 3.34 | 23.07% |
6 Months | 9.64 | 18.85 | 9.50 | 14.61 | 1,041,734 | 8.18 | 84.85% |
1 Year | 10.34 | 18.85 | 9.50 | 14.11 | 909,390 | 7.48 | 72.34% |
3 Years | 8.30 | 18.85 | 1.05 | 7.96 | 951,266 | 9.52 | 114.70% |
5 Years | 1.09 | 18.85 | 1.03 | 7.65 | 809,221 | 16.73 | 1,534.86% |
Avadel Pharmaceuticals Description
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States. |